Web Exclusives

Running a financially successful practice in community oncology is challenging. Learn more about revenue cycle management (RCM). Read More ›

On December 12, 2019, the FDA issued draft guidance to implement amendments to the Federal Food, Drug, and Cosmetic (FD&C) Act that will facilitate early assessment of studies of molecularly targeted oncology drugs that may be effective in the treatment of pediatric cancers. Read More ›

Chicago, IL—Reduced-dose chemotherapy is as effective as full-dose chemotherapy for frail elderly patients with advanced gastroesophageal cancer, according to results of the phase 3 GO2 clinical trial presented at ASCO 2019. Lower doses of oxaliplatin plus capecitabine (OCap) led to similar survival outcomes and improved quality of life compared with higher doses of that regimen. Read More ›

Since July 2016, more than 170 oncology practices across the United States have been participating in the Oncology Care Model (OCM), the Center for Medicare & Medicaid Innovation (CMMI)’s 5-year pilot program designed to deliver higher quality, more coordinated oncology care at the same or lower cost. When practices elected to participate in the OCM, they knew they would eventually have to decide whether to accept 2-sided risk or leave the program, if a performance-based payment was not achieved. Read More ›

San Francisco, CA—People who are less engaged in their own medical care have more negative health consequences, including higher readmission rates, poor care coordination, and less confidence. It is therefore imperative to keep patients engaged in their own healthcare, and current technology plays an important role in achieving this goal, according to Sangeeta Agarawal, RN, CAS, MS, Founder and Chief Executive Officer, Helpsy Health, San Francisco, CA. Read More ›

On December 3, 2019, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to the biopharmaceutical company Adaptimmune Therapeutics for ADP-A2M4 for the treatment of synovial sarcoma. Earlier this year, the FDA granted Orphan Drug Designation to the agent for the treatment of soft tissue sarcomas. Read More ›

While Medicare Part D enrollees may see their out-of-pocket expenses, deductibles, and premiums increase in 2020, protections of the drugs used in cancer treatment will remain in place. Read More ›

The rise in the number of cancer drugs taken orally has placed a renewed focus on the importance—and challenges—of patient adherence to self-administered oral medications. Read More ›

BRCA wild-type tumors are more common in women with ovarian cancer and may need higher doses of the tumor-targeting PARP inhibitor. Read More ›

The ovarian cancer patients’ internal dialogue may delay a cancer diagnosis and can also overestimate the capability of chemotherapy. Read More ›